Avid Bioservices Inc (CDMO)

[biopharm]

Yes I agree and I would say those patients, not to reach MOS, that were in Sunrise phase III (which now would become well known to have their immune cells primed via PS Targeting ...) and doing much better than those that were not in the Bavituximab arm.....

would and should convince Dr Laura E Benjamin and others...that IO combo must use PS Targeting in order to beat out MOS

The FDA should know as well and wonder why the FDA has decided not to let the public know ?